Open Thu 8:30am: 01582 842096

Fortekor Tablets for Dogs & Cats

Fortekor Tablets for Dogs & Cats

Fortekor is a medication which can be used on cats or dogs but for different ailments. For dogs it is a heart failure medication and in cats is used to treat kidney failure. Dogs that use the medication may have a significantly increased lifespan and cats will find they have an increased appetite and general quality of life. Fortekor works by improving and increasing blood flow throughout the body, essential in both heart and kidney problems.

Fortekor is a small tablet which can be administered on its own or with food for ease and is available in a number of strengths depending on the size of the animal.

There can be some side effects to the medication. Cats may put on weight while using the drug but this is a positive side effect as they may have suffered weight loss with a kidney condition in the first place. Some dogs have suffered fatigue and mild dizziness but no stronger side effects have been noted in animals using the medication. There is a possibility of interaction with other drugs, so animals already on medication should be regularly monitored by a vet.

Fortekor is a prescription-only medication, which means a vet must write a prescription for it. However, it is possible to buy pet drugs online and VioVet supplies discount pet medication. The drug can also be obtained from your veterinary surgeon but this is often the most expensive way of purchasing medication. The prescription must be obtained from the vet and sent to VioVet before you can be supplied with the drug.

Description

Fortekor 2.5 for Cats and Dogs

Presentation

Fortekor 2.5 mg

Beige, ovaloid, divisible, palatable tablet scored on both sides: 2.5 mg benazepril hydrochloride.

Uses

FORTEKOR is indicated for the treatment of congestive heart failure in dogs and reduction of proteinuria associated with chronic kidney disease in cats. The active ingredient is benazepril hydrochloride. After oral administration of benazepril hydrochloride, peak levels of benazepril are attained rapidly and decline quickly as the active substance is partially metabolised by liver enzymes to benazeprilat, a highly specific and potent angiotensin converting enzyme (ACE) inhibitor. Benazaprilat inhibits the conversion of inactive angiotensin I into active angiotensin II and thereby also reduces the synthesis of aldosterone. Therefore, it blocks effects mediated by angiotensin II and aldosterone, including vasoconstriction of both arteries and veins, retention of sodium and water by the kidney and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes).

In dogs with congestive heart failure, FORTEKOR reduces the blood pressure and volume load on the heart. Benazeprilat is excreted 54% by the biliary and 46% via the urinary route in dogs and 85% via the biliary and 15% via the urinary route in cats. The clearance of benazeprilat is not affected in dogs or cats with impaired renal function and therefore no adjustment of the dose of FORTEKOR is necessary in either species in cases of renal insufficiency.

In cats with chronic kidney disease, Fortekor significantly reduces the levels of urine protein and urine protein to creatinine ratio (UPC); this effect is probably mediated via reduced glomerular hypertension and beneficial effects on the glomerular basement membrane. However, no effect of FORTEKOR on survival in cats with CKD has been shown. FORTEKOR has also been shown to increase the appetite of cats, particularly in more advanced cases.

Dosage and administration

FORTEKOR should be given orally once daily, with or without food. The duration of treatment is unlimited.

FORTEKOR 2.5 mg tablets are flavoured and are taken voluntarily by most dogs and cats.

Dogs

FORTEKOR should be administered orally at a minimum dose of 0.25 mg (range 0.25-0.5 mg) benazepril hydrochloride/kg body weight, once daily according to the following table:

Weight of Dog (kg) FORTEKOR 2.5 mg

Standard dose

Double dose

2.5 - 5

0.5 tablet

1 tablet

> 5 - 10

1 tablet

2 tablets

The dose may be doubled, still administered once daily, to a minimum dose of 0.5 mg/kg (range 0.5-1.0) if judged clinically necessary and advised by the veterinary surgeon. FORTEKOR may be given in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary medicinal products without demonstrable adverse interactions.

Cats

FORTEKOR should be administered orally at a minimum dose of 0.5 mg (range 0.5-1.0) benazepril hydrochloride/kg body weight, once daily according to the following table:

Weight of cat (kg)

FORTEKOR 2.5

2.5 - 5

1 tablet

> 5 - 10

2 tablets

Contra-indications, warnings, etc

Do not use during pregnancy or lactation. The safety of FORTEKOR has not been established in breeding, pregnant or lactating dogs and cats. Benazepril reduced ovary/oviduct weights in cats when administered daily at 10 mg/kg body weight for 52 weeks.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure.

Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.

The efficacy and safety of FORTEKOR has not been established in dogs and cats below 2.5 kg body weight.

For animal treatment only. For oral use only. Wash hands after use. In case of accidental oral ingestion, seek medical advice immediately and show the label or the package leaflet to the physician. Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans.

In double-blind clinical trials in dogs with congestive heart failure, FORTEKOR was well tolerated with an incidence of adverse reactions lower than observed in placebo-treated dogs. No evidence of renal toxicity of the veterinary medicinal product has been observed (in dogs or cats) during clinical trials, however, as is routine in cases of chronic kidney disease, it is recommended to monitor plasma creatinine, urea and erythrocyte counts during therapy.

A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue.

In cats and dogs with chronic kidney disease, FORTEKOR may increase plasma creatinine concentrations at the start of therapy. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.

FORTEKOR may increase food consumption and body weight in cats. Emesis, anorexia, dehydration, lethargy and diarrhoea have been reported in rare occasions in cats.

In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal function. The combination of FORTEKOR and other anti-hypertensive agents (e.g. calcium channel blockers, beta-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. Therefore, concurrent use of NSAIDs or other medications with a hypotensive effect should be considered with care. Renal function and signs of hypotension (lethargy, weakness etc.) should be monitored closely and treated as necessary.

Interactions with potassium preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using FORTEKOR in combination with a potassium sparing diuretic because of the risk of hyperkalaemia.

Pharmaceutical precautions

Store in a dry place. Do not store above 25°C. Each time an unused half tablet is stored, it should be returned to the open blister space, inserted back into the cardboard box and kept in a safe place out of the reach and sight of children.

Legal category

POM-V

Packaging Quantities

PVC/PE/PVdC-aluminium blisters with 14 tablets/blister. Cardboard box with:

2 blisters

4 blisters

Further information

Disposal

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Marketing authorisation numbers

Vm 12501/4129.

Fortekor Flavour 20 mg Tablets for dogs

Presentation

Fortekor Flavour 20 mg.

Beige to light brown, ovaloid, divisible, tablet scored on both sides.

The tablets can be divided into equal halves.

20mg benazepril hydrochloride (Fortekor Flavour 20 mg).

Uses

FORTEKOR Flavour is indicated for the treatment of congestive heart failure in dogs. The active ingredient is benazepril hydrochloride. After oral administration of benazepril hydrochloride, peak levels of benazepril are attained rapidly and decline quickly as the active substance is partially metabolised by liver enzymes to benazeprilat, a highly specific and potent angiotensin converting enzyme (ACE) inhibitor. Benazeprilat inhibits the conversion of inactive angiotensin I into active angiotensin II and thereby also reduces the synthesis of aldosterone. Therefore, it blocks effects mediated by angiotensin II and aldesterone, including vasoconstriction of both arteries and veins, retention of sodium and water by the kidney and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes).

In dogs with congestive heart failure, FORTEKOR Flavour reduces the blood pressure and volume load on the heart. Benazeprilat is excreted 54% by the biliary and 46% via the urinary route in dogs. The clearance of benazeprilat is not affected in dogs with impaired renal function and therefore no adjustment of the dose of FORTEKOR Flavour is necessary in cases of renal insufficiency.

Dosage and administration

FORTEKOR flavour should be given orally once daily, with or without food. The duration of treatment is unlimited.

FORTEKOR flavour 20 mg tablets are flavoured and are taken voluntarily by most dogs.

FORTEKOR flavour should be administered orally at a minimum dose of 0.25 mg (range 0.25-0.5) benazepril hydrochloride/kg bodyweight once daily, according to the following table:

Weight of Dog (kg) Fortekor Flavour 20

Standard dose

Double dose

>20-40

0.5 tablet

1 tablet

>40-80

1 tablet

2 tablets

The dose may be doubled, still administered once daily to a minimum dose of 0.5 mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary surgeon. FORTEKOR Flavour has been given in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary medicinal products without demonstrable adverse interactions.

Contra-indications, warnings, etc

Do not use during pregnancy or lactation. The safety of FORTEKOR has not been established in breeding, pregnant or lactating dogs.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure.

Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.

The efficacy and safety of FORTEKOR has not been established in dogs below 2.5 kg body weight.

For animal treatment only. For oral use only. Wash hands after use. In case of accidental oral ingestion, seek medical advice immediately and show the label or the package leaflet to the physician. Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans.

In double-blind clinical trials in dogs with congestive heart failure, FORTEKOR was well tolerated with an incidence of adverse reactions lower than observed in placebo-treated dogs. No evidence of renal toxicity of the veterinary medicinal product has been observed in dogs during clinical trials, however, as is routine in cases of chronic kidney disease, it is recommended to monitor plasma creatinine, urea and erythrocyte counts during therapy.

A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue.

In dogs with chronic kidney disease, FORTEKOR may increase plasma creatinine concentrations at the start of therapy. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.

In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal function. The combination of FORTEKOR and other anti-hypertensive agents (e.g. calcium channel blockers, beta-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. Therefore, concurrent use of NSAIDs or other medications with a hypotensive effect should be considered with care. Renal function and signs of hypotension (lethargy, weakness etc.) should be monitored closely and treated as necessary.

Interactions with potassium preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using FORTEKOR in combination with a potassium sparing diuretic because of the risk of hyperkalaemia.

Pharmaceutical precautions

The veterinary medicinal product does not require any special storage conditions.

Each time an unused half tablet is stored, it should be returned to the open blister space, inserted back into the cardboard box and kept in a safe place out of the reach and sight of children. Tablet halves should be used within 2 days.

Legal category

POM-V

Packaging Quantities

14 tablets per aluminium/aluminium blister. Cardboard box with:

2 blisters (28 tablets)

4 blisters (56 tablets)

Further information

Disposal

Any unused veterinary medicinal product or waste material derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Marketing authorisation number

Vm 12501/4168.

Fortekor Flavour 5 mg tablets for cats and dogs

Presentation

Fortekor Flavour 5 mg.

Beige to light brown, ovaloid, divisible, tablet scored on both sides.

The tablets can be divided into equal halves.

5 mg benazepril hydrochloride.

Uses

FORTEKOR is indicated for the treatment of congestive heart failure in dogs and reduction of proteinuria associated with chronic kidney disease in cats. The active ingredient is benazepril hydrochloride. After oral administration of benazepril hydrochloride, peak levels of benazepril are attained rapidly and decline quickly as the active substance is partially metabolised by liver enzymes to benazeprilat, a highly specific and potent angiotensin converting enzyme (ACE) inhibitor. Benazaprilat inhibits the conversion of inactive angiotensin I into active angiotensin II and thereby also reduces the synthesis of aldosterone. Therefore, it blocks effects mediated by angiotensin II and aldosterone, including vasoconstriction of both arteries and veins, retention of sodium and water by the kidney and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes).

In dogs with congestive heart failure, FORTEKOR reduces the blood pressure and volume load on the heart. Benazeprilat is excreted 54% by the biliary and 46% via the urinary route in dogs and 85% via the biliary and 15% via the urinary route in cats. The clearance of benazeprilat is not affected in dogs or cats with impaired renal function and therefore no adjustment of the dose of FORTEKOR is necessary in either species in cases of renal insufficiency.

In cats with chronic kidney disease, Fortekor significantly reduces the levels of urine protein and urine protein to creatinine ratio (UPC); this effect is probably mediated via reduced glomerular hypertension and beneficial effects on the glomerular basement membrane. However, no effect of FORTEKOR on survival in cats with CKD has been shown. FORTEKOR has also been shown to increase the appetite of cats, particularly in more advanced cases.

Dosage and administration

FORTEKOR Flavour should be given orally once daily, with or without food. The duration of treatment is unlimited. FORTEKOR Flavour 5 mg tablets are flavoured and are taken voluntarily by most dogs and cats.

Dogs

Fortekor should be administered orally at a minimum dose of 0.25 mg (range 0.25-0.5) benazepril hydrochloride / kg bodyweight once daily, according to the following table:

Weight of Dog (kg) FORTEKOR Flavour 5

Standard dose

Double dose

>5-10

0.5 tablet

1 tablet

>10-20

1 tablet

2 tablets

The dose may be doubled, still administered once daily, to a minimum dose of 0.5 mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary surgeon. FORTEKOR Flavour has been given in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary products without demonstrable adverse interactions.

Cats

FORTEKOR Flavour should be administered orally at a minimum dose of 0.5 mg (range 0.5-1.0) benazepril hydrochloride/kg body weight, once daily according to the following table:

Weight of cat (kg)

FORTEKOR Flavour 5 mg

2.5 - 5

0.5 tablet

> 5 - 10

1 tablet

Contra-indications, warnings, etc

Do not use during pregnancy or lactation. The safety of FORTEKOR has not been established in breeding, pregnant or lactating dogs and cats. Benazepril reduced ovary/oviduct weights in cats when administered daily at 10 mg/kg body weight for 52 weeks.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure.

Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.

The efficacy and safety of FORTEKOR has not been established in dogs and cats below 2.5 kg body weight.

For animal treatment only. For oral use only. Wash hands after use. In case of accidental oral ingestion, seek medical advice immediately and show the label or the package leaflet to the physician. Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans.

In double-blind clinical trials in dogs with congestive heart failure, FORTEKOR was well tolerated with an incidence of adverse reactions lower than observed in placebo-treated dogs. No evidence of renal toxicity of the veterinary medicinal product has been observed (in dogs or cats) during clinical trials. However, as is routine in cases of chronic kidney disease, it is recommended to monitor plasma creatinine, urea and erythrocyte counts during therapy.

A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue.

In cats and dogs with chronic kidney disease, FORTEKOR may increase plasma creatinine concentrations at the start of therapy. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.

FORTEKOR may increase food consumption and body weight in cats. Emesis, anorexia, dehydration, lethargy and diarrhoea have been reported in rare occasions in cats.

In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal function. The combination of FORTEKOR and other anti-hypertensive agents (e.g. calcium channel blockers, beta-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. Therefore, concurrent use of NSAIDs or other medications with a hypotensive effect should be considered with care. Renal function and signs of hypotension (lethargy, weakness etc.) should be monitored closely and treated as necessary.

Interactions with potassium preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using FORTEKOR in combination with a potassium sparing diuretic because of the risk of hyperkalaemia.

Pharmaceutical precautions

Do not store above 25°C.

Each time an unused half tablet is stored, it should be returned to the open blister space, inserted back into the cardboard box and kept in a safe place out of the reach and sight of children. Tablet halves should be used within 2 days.

Legal category

POM-V

Packaging Quantities

14 tablets per aluminium/aluminium blister. Cardboard box with:

2 blisters (28 tablets)

4 blisters (56 tablets)

Further information

Disposal

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Marketing authorisation number

Vm 12501/4167.

Need help or advice? Contact us:

  • Freephone: 0800 084 2608
  • Mon - Fri: 8:30am - 7:00pm
  • Sat: 9:00am - 3:00pm
  • Email: support@viovet.co.uk

All prices include VAT where applicable.

Reviews of Fortekor Tablets for Dogs & Cats

Read our customers' reviews of Fortekor Tablets for Dogs & Cats

Questions & Answers for Fortekor Tablets for Dogs & Cats

There are currently no questions for Fortekor Tablets for Dogs & Cats - be the first to ask one!

Ask A Question

Related products: